• Novanta to buy Riverpoint Medical from Arlington Capital Partners for USD 1.2 billion cash upfront, with a USD 250 million milestone in Q1 2027.
• Closing targeted for Q3 2026; Riverpoint to be reported in the Medical Solutions segment.
• Deal aimed at expanding minimally invasive surgical consumables, doubling recurring medical consumables revenue to about USD 300 million.
• Financing planned from cash, an existing credit facility, and a recently completed USD 300 million equity raise.
• Riverpoint expected to deliver about USD 80 million adjusted EBITDA in 2027 including synergies; Novanta targets over USD 80 million cumulative synergies over five years.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novanta Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606090600BIZWIRE_USPR_____20260609_BW749750) on June 09, 2026, and is solely responsible for the information contained therein.